Mechanism of evasion by ovarian cancers from anti-VEGF therapy
卵巢癌逃避抗 VEGF 治疗的机制
基本信息
- 批准号:9302312
- 负责人:
- 金额:$ 36.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAngiogenic FactorAscitesBenchmarkingBiological AssayBiological MarkersBody FluidsCancer PatientCancer cell lineCarcinomatosisCell SurvivalClinicalClinical ManagementDiagnosisDiseaseElectron MicroscopyEndothelial CellsEquus caballusFDA approvedGoalsGrowth FactorIn VitroMalignant neoplasm of ovaryMeasuresMediatingMembraneMonitorNormal CellPatient SelectionPatientsPeritonealPlatinumPlayProgression-Free SurvivalsProteinsRNARecurrenceRegulationRelapseReportingResearch PersonnelResistanceRoleSignal PathwaySignal TransductionSpecimenStromal CellsTubeTumor AngiogenesisVEGFA geneVesicleWomanXenograft Modelbasebevacizumabcancer cellcell typechemotherapydesignexosomeexperiencehumanized antibodyhumanized monoclonal antibodiesin vivo Modelinsightmigrationmultidisciplinaryneutralizing antibodyneutralizing monoclonal antibodiesovarian neoplasmprototyperesponsestemstructural biologytargeted agenttaxanetumortumor growthtumor progression
项目摘要
PROJECT SUMMARY
The majority of women who are diagnosed with ovarian cancer present with ascites and disseminated disease
and relapse within 18 months after conventional platinum-based chemotherapy. Bevacizumab is a humanized
antibody that was approved in 2014 for treating platinum-resistant recurrent ovarian cancer and has also been
found to increase progression-free survival when combined with conventional chemotherapy as front-line
treatment. Bevacizumab neutralizes vascular endothelial growth factor-A (VEGF), a growth factor that has well-
established roles in stimulating endothelial cell survival, migration and vessel formation and also causes
ascites accumulation. However, not all patients respond to bevacizumab and there are no biomarkers that can
reliably distinguish patients who are likely to benefit from this therapy from those who will not. We have
extensively investigated the mechanisms that control ovarian tumor progression, in particular the interactions
between ovarian cancer cells and constituents of the tumor stroma. Based on our preliminary studies, we
hypothesize that resistance to bevacizumab might stem in part from the ability of ovarian cancer cells to
produce small vesicles called exosomes that act as a `Trojan Horse' to deliver VEGF to endothelial cells
without being neutralized by bevacizumab. In Aim 1 of this project, we will validate the presence of exosomal
VEGF in ovarian cancer patients, determine the signaling mechanism of exosomal VEGF, and evaluate the
ability of exosomal VEGF to stimulate ovarian tumor angiogenesis and ascites formation in xenograft models.
In Aim 2, we will evaluate the ability of bevacizumab to block exosome-induced ovarian tumor angiogenesis
and ascites formation, and evaluate the relationship between levels of exosomal VEGF and responses to
bevacizumab in ovarian cancer xenograft models and ovarian cancer patients. Our study addresses the critical
need for biomarkers that could guide the selection of ovarian cancer patients for whom bevacizumab treatment
is most beneficial and will also provide new insights for designing more effective anti-angiogenic therapies.
项目概要
大多数被诊断患有卵巢癌的女性会出现腹水和播散性疾病
传统铂类化疗后 18 个月内复发。贝伐珠单抗是一种人源化
该抗体于 2014 年被批准用于治疗铂耐药复发性卵巢癌,
发现与常规化疗联合作为一线疗法可增加无进展生存期
治疗。贝伐珠单抗可中和血管内皮生长因子-A (VEGF),这是一种具有良好作用的生长因子。
在刺激内皮细胞存活、迁移和血管形成中已确定的作用,并且还导致
腹水积聚。然而,并非所有患者都对贝伐珠单抗有反应,并且没有生物标志物可以
可靠地区分可能从该疗法中受益的患者与不会受益的患者。我们有
广泛研究了控制卵巢肿瘤进展的机制,特别是相互作用
卵巢癌细胞和肿瘤基质成分之间的关系。根据我们的初步研究,我们
假设对贝伐珠单抗的耐药性可能部分源于卵巢癌细胞的能力
产生称为外泌体的小囊泡,充当“特洛伊木马”将 VEGF 传递至内皮细胞
不被贝伐珠单抗中和。在该项目的目标 1 中,我们将验证外泌体的存在
卵巢癌患者中的 VEGF,确定外泌体 VEGF 的信号机制,并评估
外泌体 VEGF 在异种移植模型中刺激卵巢肿瘤血管生成和腹水形成的能力。
在目标 2 中,我们将评估贝伐珠单抗阻断外泌体诱导的卵巢肿瘤血管生成的能力
和腹水形成,并评估外泌体 VEGF 水平与对腹水的反应之间的关系
贝伐单抗在卵巢癌异种移植模型和卵巢癌患者中的作用。我们的研究解决了关键问题
需要可以指导选择接受贝伐珠单抗治疗的卵巢癌患者的生物标志物
是最有益的,也将为设计更有效的抗血管生成疗法提供新的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Honami Naora其他文献
Honami Naora的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Honami Naora', 18)}}的其他基金
Boosting anti-tumor immunity in the omentum for metastasis prevention
增强大网膜的抗肿瘤免疫力以预防转移
- 批准号:
10648192 - 财政年份:2023
- 资助金额:
$ 36.6万 - 项目类别:
Isolation of miRNA-rich extracellular vesicles for liquid biopsy
分离富含 miRNA 的细胞外囊泡用于液体活检
- 批准号:
10579299 - 财政年份:2022
- 资助金额:
$ 36.6万 - 项目类别:
Isolation of miRNA-rich extracellular vesicles for liquid biopsy
分离富含 miRNA 的细胞外囊泡用于液体活检
- 批准号:
10431224 - 财政年份:2022
- 资助金额:
$ 36.6万 - 项目类别:
Impact of diagnostic peritoneal lavage on omentum metastasis
诊断性腹腔灌洗对大网膜转移的影响
- 批准号:
10286303 - 财政年份:2021
- 资助金额:
$ 36.6万 - 项目类别:
Impact of diagnostic peritoneal lavage on omentum metastasis
诊断性腹腔灌洗对大网膜转移的影响
- 批准号:
10447751 - 财政年份:2021
- 资助金额:
$ 36.6万 - 项目类别:
Pre-metastatic Omental Niche Formation in Ovarian Cancer
卵巢癌转移前网膜微环境的形成
- 批准号:
10117199 - 财政年份:2018
- 资助金额:
$ 36.6万 - 项目类别:
Pre-metastatic Omental Niche Formation in Ovarian Cancer
卵巢癌转移前网膜微环境的形成
- 批准号:
10360586 - 财政年份:2018
- 资助金额:
$ 36.6万 - 项目类别:
Pre-metastatic Omental Niche Formation in Ovarian Cancer
卵巢癌转移前网膜微环境的形成
- 批准号:
9903259 - 财政年份:2018
- 资助金额:
$ 36.6万 - 项目类别:
Mechanism of evasion by ovarian cancers from anti-VEGF therapy
卵巢癌逃避抗 VEGF 治疗的机制
- 批准号:
9152040 - 财政年份:2016
- 资助金额:
$ 36.6万 - 项目类别:
Stromal Interactions and Leukemic Risk in Myelodysplastic Syndromes
骨髓增生异常综合征中的基质相互作用和白血病风险
- 批准号:
8897103 - 财政年份:2015
- 资助金额:
$ 36.6万 - 项目类别:
相似海外基金
How angiogenic factor induces immunosuppressive cells to tumor microenvironment
血管生成因子如何诱导免疫抑制细胞进入肿瘤微环境
- 批准号:
22KJ0818 - 财政年份:2023
- 资助金额:
$ 36.6万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10711027 - 财政年份:2021
- 资助金额:
$ 36.6万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10297199 - 财政年份:2021
- 资助金额:
$ 36.6万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10625314 - 财政年份:2021
- 资助金额:
$ 36.6万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10405070 - 财政年份:2021
- 资助金额:
$ 36.6万 - 项目类别:
Physiological role of anti-angiogenic factor thrombospondin in the regulation of endometrial function during early pregnancy in cattle
抗血管生成因子血小板反应蛋白在牛妊娠早期子宫内膜功能调节中的生理作用
- 批准号:
20K06385 - 财政年份:2020
- 资助金额:
$ 36.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of lymphangiogenic regulatory mechanism of angiogenic factor CCN2 through tumor-associated macrophage
阐明血管生成因子CCN2通过肿瘤相关巨噬细胞的淋巴管生成调节机制
- 批准号:
17K11866 - 财政年份:2017
- 资助金额:
$ 36.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of vascular stabilization mechanism by anti-angiogenic factor vasohibin-1
抗血管生成因子 vasohibin-1 阐明血管稳定机制
- 批准号:
15K20874 - 财政年份:2015
- 资助金额:
$ 36.6万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
angiogenic therapy for cerebral infarction with anti^sense homology derived peptide targeting angiogenic factor
靶向血管生成因子的反义同源肽治疗脑梗死
- 批准号:
15K15523 - 财政年份:2015
- 资助金额:
$ 36.6万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
The development of the anti-angiogenic factor VEGF-A165b quantification methods for cardiovascular disease.
心血管疾病抗血管生成因子 VEGF-A165b 定量方法的开发。
- 批准号:
26860367 - 财政年份:2014
- 资助金额:
$ 36.6万 - 项目类别:
Grant-in-Aid for Young Scientists (B)